The Chemo-sero-therapeutic Research Institute

Tokushima University

The University of Tokushima

Japan As Represented by Director-general of National Institute of Infectious Diseases

Yoshitaka Goto

Sachio Okuda

Yasushi Torii

Motohide Takahashi

Miho Shinmura

Shinji Nakahira

Shunji Kozaki

Tetsuhiro Harakawa

Hirotoshi Nakano

Ryuji Kaji

Satomi Munechika

Shunji Kosaki

Akihiro Ginnaga

A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin. The method includes administering 150 kDa type A neurotoxin from type A2(A2 NTX) to the patient. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation containing a type A1 botulinum toxin.

Type A2 botulinum toxin preparation

A novel type Atoxin preparation is provided. A neuromuscular transmission blocking agent comprising as an active ingredient a highly purified type Atoxin fromas infant botulism pathogen and a medicament for treating a disease with a muscle overactivity comprising as an active ingredient said toxin. In particular, the medicament of the present invention, as compared to the conventional knowntoxin preparations, has rapid efficacy of potential and is less diffusive and thus, having a broader safety margin, may be used as therapeutic medicament for decreasing local, muscle overactivity in a disease with a muscle overactivity.

[object Object]

Growing community of inventors

Kumamoto, Japan

Yoshitaka Goto